← Eichor
Study identifier: NCT06835868 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Neuro-Pain Provides a Dynamic and Interactive Register for the Invasvive Neuromodulatory Therapies for Different Chronic Pain Syndromes. Patients Living in Belgium and Suffering From Persistent Spinal Pain Syndromes Type 2 as Well as Suffering From Complex Regional Pain Syndromes Are Included.

Condition: Chronic Pain Syndromes · CRPS  ·  Sponsor: University Hospital, Antwerp

PhaseN/A
Planned participants7000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Patients suffereing from chronic pain due to persistent spinal pain syndromes or complex regional pain syndromes and living in Belgium will be included in this register once they are being considered for a treatment with invasive neuromodulation (either spinal cord stimulation either dorsal root ganglion stimulation). The screening process, the multidisciplinary evaluation, the trial therapy and the long-terl follow-up will be monitored through this register.

This description comes directly from the study's public registry record.

Talk to the study team

Guy H HANS, MD, PhD  ·  003238213000  ·  guy.hans@uza.be

Lisa Bernaerts  ·  00323821300  ·  lisa.bernaerts@uza.be

Always discuss trial participation with your own doctor first.

Locations (1)

UZA, multidisciplinary pain centerEdegem, Antwerp, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06835868